Quality of Life Studies Trials: NATERA:
The usage of cell free DNA test for monitoring tumor response or minimal residual disease in pan-tumor types.
Pediatric Oncology Trials: APEC14B1: The Project: Everychild Protocol: A Registry; Eligibility Screening; Biology and Outcome Study
Aim: A childhood cancer registry of infants, children, adolescents, and young adults with cancer called Project:EveryChild, which supports current and future therapeutic clinical trials and the discovery efforts that will lead to more effective therapies, prevention, earlier detection and reductions in early and late effects of treatment.
Pediatric Oncology Trials: AALL1732: Phase III
Aim: A study to test if the addition of Inotuzumab Ozogamicin (InO) to standard chemotherapy treatment in patients diagnosed with National Cancer Institute (NCI) High-Risk (HR) B-cell Acute Lymphoblastic Leukemia (B-ALL) or NCI Standard-Risk (SR) BALL with high risk features improves outcomes.
Pediatric Oncology Trials: AALL1631: Phase III
Aim: A study of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones
Pediatric Oncology Trials: ANBL1531: Phase III
Aim: Testing the addition of I-MIBG or Crizotinib to intensive therapy in children and adults with high-risk neuroblastoma (NBL)
Pediatric Oncology Trials: AAML1831 – Phase III
A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations
Pediatric Oncology Trials: AALL1821 – Phase II
A Phase 2 Study of Blinatumomab (NSC# 765986, IND# 125462) in Combination with Nivolumab (NSC # 748726, IND# 125462), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged ≥ 1 to < 31 Years Old with First Relapse
Pediatric Oncology Trials: AALL 1621
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND#133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B- ALL)
Pediatric Oncology Trials: AGCT 1531
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
Pediatric Oncology Trials: ACCL 2031
A Phase 3 Randomized, Placebo-Controlled Trial Evaluating Memantine (IND# 149832) for Neurocognitive Protection in Children Undergoing Cranial Radiotherapy as Part of Treatment for Primary Central Nervous System Tumors